“We're going to continue to take share. There's plenty of opportunity for share gain, not just in respiratory testing.”

In context

“what this patient has. And ultimately, with the 4-in-1 test, the doctor is not only able to identify what it is not, it specifically identifies what the ailment is and allows a therapeutic decision. And this is done with ease-of-use. This is done at a short turnaround time and its high performance, meaning it's the right answer. And that combination has really been attractive to hospital systems and clinicians throughout the world and really defines how Cepheid continues to move forward and take share. Michael Ryskin: So, with all that being said, where does Cepheid go next? You talked about the massive growth in the install base. You talked about the menu expansion. Margins have really taken a huge leap forward. So, what's your view of Cepheid over the next couple of years? Rainer Blair: We're going to continue to take share. There's plenty of opportunity for share gain, not just in respiratory testing. On the contrary, we have many more tests available. So, we continue with ensuring that the utilization of more menu assays per instrument, as well as introducing additional assays. And then, of course, we still have the opportunity of geographic expansion. So, we're going to continue to invest in the right clinical decision-making for the hospital systems and doctors out there by providing them this outstanding solution. Michael Ryskin: So, net-net, above company growth, margin accretive at this point, right? Rainer Blair: So, we think the long-term growth rate of the non-respiratory business is in the low double-digits. That is above the fleet's growth rate, which we believe to be high single digits. And this is a very profitable business at scale and will contribute and be accretive to”